The previously-mentioned angiopoietin-like protein-3 (ANGPTL3) inhibitors (evinacumab) recently introduced in familial hypercholesterolemia follow the same development route as PCSK9 modulators [115]. Here, ANGPTL3 is linked to familial hypercholesterolemia.